Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

8.7K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.7K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

8.3K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
8.3K
Erythropoiesis01:14

Erythropoiesis

5.7K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
5.7K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

3.1K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.0K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.0K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Bifunctional Small Molecule Degrader of the Long Noncoding RNA MALAT1 Triplex.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Evolution of Pliocene-Pleistocene tropical terrestrial Andean temperature amplification.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Ribosomal RNA methylation in HSCs: it's so "good for you".

Blood·2026
Same author

Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma.

Cancers·2026
Same author

GlycoRNA complexed with heparan sulfate regulates VEGF-A signalling.

Nature·2026
Same author

Differential Clearance of [<sup>177</sup>Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair Inhibitors.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Jan 17, 2026

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

15.9K

Epitranscriptomic advances in normal and malignant hematopoiesis.

Maria Eleftheriou1,2,3, James Russell1,2, Konstantinos Tzelepis4,5,6,7

  • 1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.

Leukemia
|September 19, 2025
PubMed
Summary
This summary is machine-generated.

RNA modifications, or the epitranscriptome, regulate blood cell development and cancer. Targeting these RNA marks and their enzymes shows promise for treating hematological cancers and improving diagnostics.

More Related Videos

Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis
12:44

Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis

Published on: November 11, 2014

12.7K
Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

906

Related Experiment Videos

Last Updated: Jan 17, 2026

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

15.9K
Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis
12:44

Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis

Published on: November 11, 2014

12.7K
Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

906

Area of Science:

  • Molecular Biology
  • Epigenetics
  • Hematology

Background:

  • RNA modifications form the epitranscriptome, a regulatory layer controlling RNA fate.
  • These modifications are crucial in hematopoietic stem cell function, lineage development, and immunity.
  • Dysregulation of RNA modifications is implicated in leukemia progression and therapeutic resistance.

Purpose of the Study:

  • To review RNA modifications and editing events relevant to normal and malignant hematopoiesis.
  • To highlight specific modifications (m⁶A, m⁵C, m⁷G, ac⁴C, Ψ, A-to-I editing, RNA glycosylation) and enzymes (METTL3, METTL1, ADAR1, NAT10).
  • To discuss the therapeutic potential of targeting RNA-modifying enzymes in blood cancers.

Main Methods:

  • Literature review focusing on RNA modifications in hematopoiesis.
  • Analysis of the roles of specific RNA modifications and enzymes in leukemia.
  • Examination of emerging therapeutic strategies and diagnostic applications.

Main Results:

  • Specific RNA modifications and enzymes like METTL3 are critical for leukemic stem cell programs, immune evasion, and treatment resistance.
  • Inhibitors targeting RNA-modifying enzymes are in clinical development, showing therapeutic promise.
  • Epitranscriptomic profiling can enhance disease stratification and minimal residual disease monitoring.

Conclusions:

  • RNA modifications are central to blood cancer biology.
  • Targeting the epitranscriptome offers new avenues for hematological cancer therapy.
  • Integrating epitranscriptomic data can improve diagnostics and treatment strategies.